康方生物再次赢下头对头临床研究 中国创新药在全球肺癌诊疗上挑起大梁

每日经济新闻
Apr 23, 2025

康方生物双抗药物依沃西单抗(PD-1/VEGF双抗)又一次在头对头试验中战胜了PD-1,这次挑战的对象是百济神州的替雷利珠单抗联合疗法。  消息显示,依沃西单抗联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的注册性三期临床研究(AK112-306/HARMONi-6),头对头试验显示强阳性结果,研究结果具有统计学显著获益和重大临床获益。  肺鳞癌占所有肺癌病例数的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10